Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry
- PMID: 21958049
- DOI: 10.1111/j.1365-2265.2011.04243.x
Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry
Abstract
Context: Primary aldosteronism (PA) is mainly caused by aldosterone-producing adenoma and idiopathic bilateral adrenal hyperplasia (IHA). Recently, spontaneous resolution of IHA has been described.
Objective: We aimed to determine the frequency of spontaneous remission of PA during long-term treatment with mineralocorticoid receptor (MR) antagonists.
Design, setting and patients: Thirty-seven patients of the Munich PA registry with IHA treated by MR antagonists were investigated. The patients were identified retrospectively by chart review and prospectively assessed by clinical and biochemical means.
Main outcome measures: Complete remission of IHA was defined as normal aldosterone to renin ratio (ARR), normal suppression test and normalization of hypokalaemia in the presence of normal blood pressure. Partial remission was defined as normalization of normal ARR, normal suppression test and normalization of hypokalaemia in the presence of persistent hypertension.
Results: The mean period of MR antagonist treatment was 5·8 ± 0·7 years in the patients. We identified two of 37 (5·4%) patients with spontaneous remission: one with complete remission and one with partial remission.
Conclusion: Remission of IHA in PA may occur in some patients after long-term mineralocorticoid antagonist treatment.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.J Clin Endocrinol Metab. 2012 Apr;97(4):1109-13. doi: 10.1210/jc.2011-2563. Epub 2012 Feb 15. J Clin Endocrinol Metab. 2012. PMID: 22337911
-
Primary aldosteronism: renaissance of a syndrome.Clin Endocrinol (Oxf). 2007 May;66(5):607-18. doi: 10.1111/j.1365-2265.2007.02775.x. Clin Endocrinol (Oxf). 2007. PMID: 17492946 Review.
-
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.J Hypertens. 2007 Jan;25(1):177-86. doi: 10.1097/HJH.0b013e3280108e6f. J Hypertens. 2007. PMID: 17143190
-
Primary aldosteronism -- screening, diagnosis and therapy.Cor Vasa. 1981;23(4):265-79. Cor Vasa. 1981. PMID: 7028394
-
[Investigation of hyperaldosteronism in the hypertensive patient. Why? When? How?].Arch Mal Coeur Vaiss. 2003 Jan;96(1):37-42. Arch Mal Coeur Vaiss. 2003. PMID: 12613148 Review. French.
Cited by
-
Some Considerations About Primary Aldosteronism and Its Follow-Up.J Clin Hypertens (Greenwich). 2016 Dec;18(12):1213-1215. doi: 10.1111/jch.12911. Epub 2016 Oct 19. J Clin Hypertens (Greenwich). 2016. PMID: 27759185 Free PMC article. No abstract available.
-
Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism.Endocrine. 2016 Dec;54(3):826-829. doi: 10.1007/s12020-015-0822-4. Epub 2015 Dec 8. Endocrine. 2016. PMID: 26645815 No abstract available.
-
Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.Front Endocrinol (Lausanne). 2025 Jan 14;15:1372683. doi: 10.3389/fendo.2024.1372683. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39877848 Free PMC article. Review.
-
Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review.Int J Mol Sci. 2022 Nov 10;23(22):13821. doi: 10.3390/ijms232213821. Int J Mol Sci. 2022. PMID: 36430298 Free PMC article. Review.
-
DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.Int J Mol Sci. 2021 Apr 27;22(9):4587. doi: 10.3390/ijms22094587. Int J Mol Sci. 2021. PMID: 33925539 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources